Clinical trials: Tranquilizing Agents
Schizophrenia, Tranquilizing Agents
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
- Conditions
- Schizophrenia, Tranquilizing Agents, Mental Disorders, Therapeutic Uses
- Trial name
- NCT00294008
- Testing
- Risperdal Consta
- Volunteers
- 230 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.